tetano
Editor, Senior Moderator
J Immunol. 2016 Jun 8. pii: 1600497. [Epub ahead of print]
[h=1]A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.[/h] Holbrook BC[SUP]1[/SUP], Kim JR[SUP]1[/SUP], Blevins LK[SUP]1[/SUP], Jorgensen MJ[SUP]2[/SUP], Kock ND[SUP]2[/SUP], D'Agostino RB Jr[SUP]3[/SUP], Aycock ST[SUP]4[/SUP], Hadimani MB[SUP]5[/SUP], King SB[SUP]5[/SUP], Parks GD[SUP]1[/SUP], Alexander-Miller MA[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus infection of neonates poses a major health concern, often resulting in severe disease and hospitalization. At present, vaccines for this at-risk population are lacking. Thus, development of an effective vaccine is an urgent need. In this study, we have used an innovative nonhuman primate neonate challenge model to test the efficacy of a novel TLR 7/8 agonist R848-conjugated influenza virus vaccine. The use of the intact virus represents a step forward in conjugate vaccine design because it provides multiple antigenic targets allowing for elicitation of a broad immune response. Our results show that this vaccine induces high-level virus-specific Ab- and cell-mediated responses in neonates that result in increased virus clearance and reduced lung pathology postchallenge compared with the nonadjuvanted virus vaccine. Surprisingly, the addition of a second TLR agonist (flagellin) did not enhance vaccine protection, suggesting that combinations of TLR that provide increased efficacy must be determined empirically. These data support further exploration of this new conjugate influenza vaccine approach as a platform for use in the at-risk neonate population.
Copyright ? 2016 by The American Association of Immunologists, Inc.
PMID: 27279374 [PubMed - as supplied by publisher]
[h=1]A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.[/h] Holbrook BC[SUP]1[/SUP], Kim JR[SUP]1[/SUP], Blevins LK[SUP]1[/SUP], Jorgensen MJ[SUP]2[/SUP], Kock ND[SUP]2[/SUP], D'Agostino RB Jr[SUP]3[/SUP], Aycock ST[SUP]4[/SUP], Hadimani MB[SUP]5[/SUP], King SB[SUP]5[/SUP], Parks GD[SUP]1[/SUP], Alexander-Miller MA[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza virus infection of neonates poses a major health concern, often resulting in severe disease and hospitalization. At present, vaccines for this at-risk population are lacking. Thus, development of an effective vaccine is an urgent need. In this study, we have used an innovative nonhuman primate neonate challenge model to test the efficacy of a novel TLR 7/8 agonist R848-conjugated influenza virus vaccine. The use of the intact virus represents a step forward in conjugate vaccine design because it provides multiple antigenic targets allowing for elicitation of a broad immune response. Our results show that this vaccine induces high-level virus-specific Ab- and cell-mediated responses in neonates that result in increased virus clearance and reduced lung pathology postchallenge compared with the nonadjuvanted virus vaccine. Surprisingly, the addition of a second TLR agonist (flagellin) did not enhance vaccine protection, suggesting that combinations of TLR that provide increased efficacy must be determined empirically. These data support further exploration of this new conjugate influenza vaccine approach as a platform for use in the at-risk neonate population.
Copyright ? 2016 by The American Association of Immunologists, Inc.
PMID: 27279374 [PubMed - as supplied by publisher]